Join the online hackathon #VersusVirus to find solutions for the challenges linked to the new coronavirus   #VersusVirus is a…

Aktiia raises new funds to finalise last steps towards market entry   Neuchâtel-based Aktiia, created in 2018, has developed a…

European Commission seeks to delay the new EU Medical Devices Regulation (MDR)   Stella Kyriakides, the European Commissioner for Health…

Swiss Medtech companies defined as part of Switzerland’s critical infrastructure   The Federal Department of Defence, Civil Protection and Sport…

Rheon Medical to launch its eyeWatch product on the Swiss and EU markets   The Vaud-based startup, Rheon Medical, specialised…

1Drop brings medical diagnostics to space   The Neuchâtel-based company, 1Drop Diagnostics, which specialises in the detection of cardiovascular biomarkers…

Teams from UNIFR & SICHH discover a new Alzheimer diagnosis solution based on saliva analysis   The University of Fribourg…

Abionic’s R&D focuses on the development of an early sepsis diagnosis solution | A tool for Coronavirus identification   Abionic,…

EBAMed joins the Mayo Clinic Business Accelerator and starts pre-clinical testing   EBAMed SA, a medical technology company enabling access…

Los Angeles – Geneva – Monthey: CSG-BIO SA (CSG-Bio), which intends to offer the most advanced and comprehensive stem cell banking services to families worldwide in the near future, took over some of CryoSave AG’s assets in 2019. It has now announced the signing of an agreement with CORDSAVINGS SA (CordSavings), the reputed independent Swiss neonatal stem cells laboratory, to secure the hundreds of thousands of stem cell samples left in insecurity following the bankruptcy of the Swiss company Cryo-Save AG in September 2019.

New appointment at SOPHiA GENETICS to accelerate the execution of its Medical Strategy   On 13 February 2020, SOPHiA GENETICS, leader…

Lunaphore closes its Series C funding   On 6 February 2020, the EPFL spin-off, Lunaphore, founded in 2014, announced the…